News
IMRX
3.710
+1.09%
0.040
Buy Rating Reiterated as Atebimetinib’s Combination Potential and Astellas Collaboration Support $14 Price Target
TipRanks · 2d ago
Immuneering to supply atebimetinib for two Astellas pancreatic cancer studies
TipRanks · 2d ago
Astellas, Immuneering Enter Pancreatic Cancer Trial Collaboration
NASDAQ · 2d ago
Immuneering Plans To Initiate Phase 2 Clinical Trial Evaluating Atebimetinib In Combination With Chemotherapy In Patients With Anaplastic Thyroid Cancer
Benzinga · 2d ago
Immuneering Enters Into Clinical Trial Collaboration And Supply Agreement To Supply Investigational MEK Inhibitor, Atebimetinib, For Two Astellas-Sponsored Studies Targeting Subset Of Pancreatic Cancer Patients
Benzinga · 2d ago
Immuneering Corporation Appoints Grant C. Bogle to Board of Directors on November 9, 2026
NASDAQ · 5d ago
Immuneering Appoints Grant C. Bogle to Board of Directors
TipRanks · 5d ago
*Immuneering Appoints Grant Bogle to Bd of Directors
Dow Jones · 5d ago
Press Release: Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
Dow Jones · 5d ago
Weekly Report: what happened at IMRX last week (1102-1106)?
Weekly Report · 5d ago
Immuneering Announces Its Atebimetinib's Data Shows Improvement In Activity Of PD-1 Checkpoint Blockade In RAS-Mutant Colorectal And Lung Cancer Models; Demonstrates 50% Durable Complete Regression In Colorectal Model
Benzinga · 11/06 14:02
Weekly Report: what happened at IMRX last week (1026-1030)?
Weekly Report · 11/02 09:22
IMRX: Maldonado Reiterates Buy Rating and Maintains $14 Price Target on Encouraging Atebimetinib Survival and Phase 3 Progress
TipRanks · 10/30 10:35
Immuneering Corporation Reports Third Quarter 2026 Financial Results and Provides Business Updates
NASDAQ · 10/30 05:08
Immuneering GAAP EPS of -$0.37 misses by $0.06
Seeking Alpha · 10/29 20:51
Immuneering reports Q3 EPS (37c), consensus (31c)
TipRanks · 10/29 20:31
Press Release: Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
Dow Jones · 10/29 20:05
Weekly Report: what happened at IMRX last week (1019-1023)?
Weekly Report · 10/26 09:22
Immuneering Has Promising Survival Data, Though Its Cash Discount Needs Scrutiny
Seeking Alpha · 10/19 11:18
Weekly Report: what happened at IMRX last week (1012-1016)?
Weekly Report · 10/19 09:22
More
Webull provides a variety of real-time IMRX stock news. You can receive the latest news about Immuneering Corp through multiple platforms. This information may help you make smarter investment decisions.
About IMRX
Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.